Literature DB >> 19763633

Differential palliative care issues in patients with primary and secondary brain tumours.

Christoph Ostgathe1, Jan Gaertner, Maren Kotterba, Sebastian Klein, Gabriele Lindena, Friedemann Nauck, Lukas Radbruch, Raymond Voltz.   

Abstract

INTRODUCTION: Cancer may affect the central nervous system either by primary or secondary brain tumours (PBT/SBT). Specific needs of these patients and special requirements of services caring for them have not been adequately addressed so far.
METHODS: Since 1999, an annual, 3-month census is being conducted in different palliative care settings throughout Germany. Pooled data from the years 2002-2005 were analysed to test for differences between patients with PBT, SBT and other palliative care patients (OP). Symptom frequencies, ECOG status and nursing needs were tested for differences (chi(2)). Free text entries for reasons for admission were recorded, categorised and analysed descriptively.
RESULTS: A total of 5,684 patients were documented (PBT n = 153, 2.7%; SBT n = 661, 11.9%; OP n = 4,872, 85.4%). For patients with PBT, poor functional status and high need for nursing support was reported more frequently than for patients with SBT and OP. For patients with PBT/SBT physical symptoms (pain, nausea, vomiting, constipation and loss of appetite) were documented less frequently and in lower intensity than for OP. However, nursing, psychological, and social problems/symptoms were documented significantly more often and showed higher intensity, particularly the patients'' need for support with the activities of daily living, disorientation/confusion of the patients and overburdening of the family. For 67% of all patients, a reason for admission was documented in free text. Main reasons were symptom control (OP>SBT>PBT), social issues (PBT>SBT>OP), functional deficits (PBT>SBT>OP) and cognitive impairment (PBT/SBT>OP). Distinct neurological deficits and problems were documented more often as secondary ICD-diagnoses than as a leading reason for admission.
CONCLUSION: The specific palliative care problems and the rationales leading to health care utilisation point to the need for an appropriate interdisciplinary and multi-professional provision of care for patients with brain malignancies, with a particular view on the needs of the families and an early integration of social and psychological support.

Entities:  

Mesh:

Year:  2009        PMID: 19763633      PMCID: PMC3128711          DOI: 10.1007/s00520-009-0735-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


Introduction

Involvement of the central nervous system is common in patients with cancer. Secondary brain tumours develop in 20–40% of systemic malignancies at some point during the illness [1]. Brain metastases significantly reduce life expectancy, with a mean survival of 1–6 months, depending on histology and applied therapies [2]. Primary brain tumours belong to the rarer neoplasms with less than 2% of the newly diagnosed cancers [3]. One fourth to one third of these are highly malignant gliomas with a median survival of 5–10 months [4, 5]. Primary or secondary brain tumours often lead to serious deterioration of neurological and cognitive functions [6]. Besides the existential distress, patients and their families suffer from fears that this condition may lead to a change or loss of individual control, cognition or consciousness, as well as the patients' personality. Palliative care addresses symptoms and problems caused by progressive, life-limiting diseases irrespective of the underlying diagnosis [7]. Due to restricted options to limit the progression of the disease for the majority of patients with primary brain tumours, especially glioblastoma, or brain metastases, the management has to focus on the best possible palliation. To meet the specific needs of these patients appropriately, a more detailed evaluation of this specific group is required. Only little information on this topic is available [8, 9], and it is neither known whether there are differences in the palliative care needs of patients with primary and secondary brain tumours nor whether differences to other palliative care patient groups exist. In this study, we analysed prospectively collected core data sets of palliative care patients (1) to detect possible variations in palliative care problems in patients with malignancies in the central nervous system compared with other patients in palliative care and (2) to determine what the essential issues for services caring for this particular patient group are.

Methods

Since 1996, a standardised basic documentation tool (Hospice and Palliative care Evaluation (HOPE)) for palliative care patients has been developed, evaluated and amended accordingly by a multi-professional working group. Each year, German inpatient and outpatient hospice and palliative care services (Table 1) are recruited to participate in a 3-month census. The participants document up to 30 consecutive palliative care patients at admission to the service and at the time of discharge or death. The anonymised data can be submitted via use of an online database or a two-page paper questionnaire and is processed centrally.
Table 1

Number of participating units and documented patients

Year200220042005Number of patients
Palliative care units5468534,182
Hospices91212653
General practitioners78342
Oncological units536281
Home care45177
Geriatric units249
Documented pts1,5672,2141,9035,684
Number of participating units and documented patients For this study, data on age, gender, diagnosis, metastases, concomitant diseases, functional status, prevalence and intensity of symptoms as well as psychological, nursing and social problems were pooled (years 2002, 2004 and 20051) and analysed. Symptoms and problems were assessed by staff via an integrated symptom checklist (Table 2) using a 4-point grading scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). This symptom checklist was constructed as part of the documentation tool for a general palliative care population, serving to document a patient's status and not to reflect specific diagnoses (for example “feeling depressed” and not “depression”). Detailed information on the development of the documentation tool has been published previously [10, 11]. HOPE was used in several epidemiological surveys in Germany [10, 12–14]. Further evaluation of the psychometric properties is currently being performed.
Table 2

Symptoms and problems assessed with Hospice and Palliative care Evaluation (HOPE)

PhysicalPain, nausea, vomiting, dyspnoea, constipation, weakness, loss of appetite, tiredness
NursingWound care, activities of daily living
PsychologicalFeeling depressed, anxiety, emotional strain, disorientation/confusion
SocialNeed for social support, overburden of family
Symptoms and problems assessed with Hospice and Palliative care Evaluation (HOPE) Patients with primary brain tumours were identified by the documented ICD10 Code and/or free text entries for the main diagnosis. Patients with secondary brain tumours could be identified as the core documentation included an item on the site of metastases. Differences between patients with primary and secondary brain tumours as well as between both groups and other patients without malignant affection of the central nervous system were analysed. Comparative analysis was performed for place of care, performance status according to the Eastern Cooperative Oncology Group (ECOG) [15], nursing levels, as well as for documented symptoms and problems. The nursing levels2 were graded according to the German legislation on long-term care in four different levels depending on type, frequency and duration of the need for nursing [16] (Table 3).
Table 3

Nursing levels according to the German long-term care legislation [16]

Level ISupport is necessary for at least two activities in the areas of personal hygiene, nutrition and mobility (at least once a day) as well as housekeeping (at least several times a week) with an overall average duration of at least 90 min/day
Level IISupport is necessary at least three times a day with an overall average duration of at least 3 h/day
Level IIISupport is necessary around the clock including nights with an overall average duration of at least 5 h/day
Level III+Cases of hardship with exceptionally high need for support
Nursing levels according to the German long-term care legislation [16] The programme packet SPSS 14.0 (SPSS Inc, Chicago, IL, USA) was used for statistical evaluation. Prevalence of symptoms and problems with higher intensity (moderate and severe) at the time of admission was determined. Group differences for these symptoms/problems, as well as for gender, place of care, levels of nursing care, ECOG were tested with chi-square, differences in age and length of stay and with ANOVA. For statistical significance we used p < 0.05 in all tests. The core data set includes free text entries for the reason for admission. These free text entries were recorded (e.g. pain, pain management, adaptation of analgesic regimen were coded as a subcategory pain) and categorised (e.g. pain and other symptoms were aggregated to a main category symptom management). As the instrument was not developed specifically for patients with brain malignancies, free text entries on reasons for admission were additionally scanned for specific neurological problems. This data was compared with neurological diagnoses documented as ICD-10 codes (seizures: G40–41; paresis: G 81–83/G 53.3; brain oedema: G93.6) to determine whether specific neurological problems were considered to be a reason for admission to palliative care. This data was evaluated descriptively only, as not for all patients a reason for admission was documented.

Results

A total of 5,684 palliative care patients were documented in the period under review. More than 50% of the German palliative care units (2002, 79 units; 2004, 106; 2005,116) [13, 17] participated. The number of participating hospices3, general practitioners, oncology wards, home care services and geriatric wards was considerably lower (Table 1). A primary brain tumour (PBT) was the main diagnosis in 151 patients (2.6%); 661 patients (11.9%) with other primary cancers had brain metastases (secondary brain tumours (SBT)) at the time of admission. The most common sites of the primary were lung (38.7%), breast (19.5%) and gastrointestinal tract (11.3%). No gender differences were detectable. Patients suffering from malignancies of the brain were significantly younger than other patients (PBT, 62.8 years ± 14.8; SBT, 63.2 years ± 12.3; other palliative care patients (OP), 68.4 years ± 12.3; PBT/SBT, n.s.; PBT/OP, F 29.1 p < 0.001; SBT/OP, F 42.4 p < 0.001).

Differential palliative care issues

Functional status (ECOG) and need for nursing differed significantly. Patients with PBT and SBT showed more frequently a poor functional status (ECOG 3–4) compared with OP (Table 4). A high need for nursing support (level III) was documented more often for patients with PBT than for OP and patients with SBT (Table 4). The length of stay until discharge or death was significantly longer (F 4.5; p = 0.035) in patients with PBT (16.8 days ± 16.1) compared with OP (14.3 days ± 14.3), but not in comparison with patients with SBT (14.5 days ± 13.4). In the period under review, significantly more patients with SBT died than OP or patients with PBT (Table 4).
Table 4

Comparison of characteristics (places of care, levels of nursing care and functional status) between the patients with primary brain tumours, secondary brain tumours and the other patients without malignant brain disease

Group differences
GroupPrimary brain tumour (PBT) N = 151Secondary brain tumour (SBT) N = 661Other patients (OP) N = 4,872PBT/SBTPBT/OPSBT/OP
Item
N%N%N%
Place of care
 Palliative care unit10368.248072.63,59973.9
 Hospice3019.910215.452110.7p < 0.001 (χ² 12.6)p < 0.001 (χ² 13.1)
 General practitioner159.9345.12936p = 0.026 (χ² 5.0)p = 0.048 (χ² 3.9)
 Oncology152.32665.5p < 0.001 (χ² 12.3)
 Home care32304.51443p = 0.029 (χ² 4.8)
 Geriatrics491
Nursing levels
 None3523.222433.92,09643p = 0.011 (χ² 6.5)p < 0.001 (χ² 23.6)p < 0.001 (χ² 19.9)
 Applied for3523.214822.485417.5p = 0.002 (χ² 9.3)
 Level I1912.68713.260712.5
 Level II2113.98212.450910.4
 Level III1811.9233.51473.0p < 0.001 (χ² 18.3)p < 0.001 (χ² 36.5)
 Level III+10.2230.5
ECOG 3 or 412890.153484.53,28971.7p < 0.001 (χ² 23.3)p < 0.001 (χ² 46.3)
Death6244.034955.22,17647.3p = 0.015 (χ² 5.9)p < 0.001 (χ² 13.9)
Comparison of characteristics (places of care, levels of nursing care and functional status) between the patients with primary brain tumours, secondary brain tumours and the other patients without malignant brain disease The analysis of symptom/problem prevalences and intensities as documented in the symptom and problem checklist also showed significant differences. Most physical symptoms (except for weakness, tiredness and dyspnea) were documented less often with moderate to severe intensity in patients with PBT/SBT compared with OP (Table 5). Need for support in the activities of daily living, symptoms of disorientation/confusion and problems with overburdening of the family were documented more often for patients with SBT and PBT (Table 5). Emotional strain and anxiety were more prevalent in patients with SBT compared with OP and patients with PBT (Table 5).
Table 5

Comparison of prevalence of symptoms and other problems with higher intensity (moderate–severe) between the patients with primary brain tumours, secondary brain tumours and the other patients without malignant brain disease

Group differences
GroupPrimary brain tumour (PBT) N = 151Secondary brain tumour (SBT) N = 661Other patients (OP) N = 4872PBT/SBTPBT/OPSBT/OP
Item
N%N%N%
Physical symptoms
 Pain4329.528944.12,59053.5p = 0.001 (χ² 10.9)p < 0.001 (χ² 33.8)p < 0.001 (χ² 20.9)
 Nausea1610.712519.21,35028p = 0.015 (χ² 5.9)p < 0.001 (χ² 21.6)p < 0.001 (χ² 22.6)
 Vomiting106.78613.390418.7p = 0.027 (χ² 4.9)p < 0.001 (χ² 13.9)p = 0.001 (χ² 11.6)
 Dyspnoea3219129.11,36528.3p < 0.001 (χ² 48.4)p < 0.001 (χ² 49.7)
 Constipation3624.720531.71,59933.5p = 0.026 (χ² 4.9)
 Weakness11780.157187.43,98182.5p = 0.021 (χ² 5.3)p = 0.002 (χ² 9.9)
 Loss of appetite6243.140863.43,17866.6p < 0.001 (χ² 20.1)p < 0.001 (χ² 34.4)
 Tiredness9867.147072.43,13765.2p < 0.001 (χ² 13.3)
Nursing problems
 Wound care2416.413521.198620.2
 Activities of daily living13992.755385.13,37570.6p = 0.014 (χ² 6.0)p < 0.001 (χ² 34.5)p < 0.001 (χ² 59.7)
Psychological problems
 Feeling depressed4532.122335.11,49431.5
 Anxiety4632.226741.71,76537p = 0.035 (χ² 4.4)p = 0.024 (χ² 5.3)
 Emotional strain5437.829746.11,98041.5p = 0.027 (χ² 4.9)
 Disorientation/confusion705022635.166914p = 0.001 (χ² 10.8)p < 0.001 (χ² 137.5)p < 0.001 (χ² 182.9)
Social problems
 Need for social support8458.734354.92,03243.2p < 0.001 (χ² 13.5)p < 0.001 (χ² 30.2)
 Overburden of family11074.341765.42,40551.5p = 0.037 (χ² 4.4)p < 0.001 (χ² 30.0)p < 0.001 (χ² 43.5)
Comparison of prevalence of symptoms and other problems with higher intensity (moderate–severe) between the patients with primary brain tumours, secondary brain tumours and the other patients without malignant brain disease

Reason for admission

In 67% (n = 3,810) of all patients, a reason for admission was documented in free text. Here, mainly symptom control (PBT, 39.2%; SBT, 57.4%; OP 69,4%), social issues (PBT, 27.8%; SBT, 18.9%; OP, 15.8%), functional deficits (PBT, 14.4%; SBT, 10.9%; OP, 5.3%) and cognitive impairment (PBT, 10.3%; SBT, 10.5%; OP, 3.5%) were documented (Table 6). Distinct neurological deficits and problems were documented more often as secondary ICD-diagnoses than as a leading reason for admission (Table 6).
Table 6

Documented neurological problems of patients with primary and secondary brain tumours on admission

Primary brain tumourSecondary brain tumourOther patients
Diagnosis (ICD)Reason for admission (free text)Diagnosis (ICD)Reason for admission (free text)Diagnosis (ICD)Reason for admission (free text)
Paresis34%2.6%10.3%2.1%2.9%0.3%
Seizures18.6%8.2%6.1%3.1%0.5%0.1%
Brain oedema6.2%5.2%1.3%1.7%0.1%0.1%
Documented neurological problems of patients with primary and secondary brain tumours on admission

Discussion

Due to the lack of curative treatment options for many patients with primary brain tumours and their reduced life expectancy, good palliative care is essential [18]. For patients with cancer of other origin, the diagnosis of secondary brain tumours frequently determines the transition from a curative to a palliative situation [19]. Yet to date, there has been no systematic evaluation and comparison of specific palliative care problems and needs of patients with central nervous neoplasms within a palliative care population based on a broad, prospectively collected data pool. The study presented here shows that symptoms and problems in patients with primary brain tumours differ significantly in prevalence and intensity from those of other palliative care patients. Patients with primary brain tumours had evidence of more advanced disease such as poorer performance status and higher levels of nursing support. However, physical symptoms, except weakness and tiredness, were documented less frequently and with lower intensity. Nursing problems and psychological problems showed little differences except for a predominance of disorientation and confusion in patients with primary brain tumours. The need for social support and overburdening of the family were significantly more often documented in patients with primary brain tumours. The lower incidence of physical symptoms may be related to underrecognition and underassessment in those patients. This could be due to the difficult symptom assessment in cognitively impaired patients. In addition, the higher rate of symptomatic treatment with steroids could lead to alleviation of some symptoms such as loss of appetite in comparison to other patient groups [20]. The higher prevalence of social problems that was found in our study may be related to more advanced disease in primary brain tumour patients. However, the care for a loved one who suffers from disorientation and confusion may also overburden families and raise the need for social support. This has been identified as a major issue in families who care for patients with brain tumours, far more than in the care for the general palliative care population. Confusion impacts significantly on the social structures, as it aggravates high levels of distress in family members [9, 21, 22]. This may lead to feelings of stress and problems of ill health in a majority of primary caretakers [9, 23]. Distress of family members may reflect the increase of responsibilities with decreasing abilities of the patient and the uncertainty of the situation [24]. These issues are not merely specific to patients receiving palliative care and their families, but to the fact that the brain is affected by a malignant tumour. Therefore, the families’ burden due to the patients' mental impairment and changed personality must be addressed appropriately already early in the course of the disease by all disciplines involved, e.g. neurooncologists, surgeons and radiotherapists. Compared with patients with primary brain tumours, the group with secondary brain tumours showed a less reduced functional status and was assigned to lower levels of nursing care. Both parameters indicate less advanced disease than in patients with primary brain tumours, but still more advanced disease than in the other patients. Similarly, the differences in symptom scores between patients with primary brain tumours and other patients may be related to the general progression of the disease rather than to the fact that brain metastases have occurred. By nature of the disease, brain metastases frequently develop along with metastases at multiple sites as one of the signs of an overall progression of the disease. This is supported by the fact that in this group, significantly more patients died in the period under review. By analysing the reasons for admission, we also wanted to explore what the essential needs are that services caring for these particular patient groups should provide. The emerging problems that lead to admission reflect some of the earlier mentioned issues. Although symptom management was the leading cause for admission in all groups, it was far less frequent in patients with primary and secondary brain malignancies than in other patients. Again, cognitive changes, functional deficits and social issues were identified far more commonly as the reason for service utilisation. Interestingly, even though specific neurological problems, such as paresis, seizures and brain oedema, were documented as ICD-diagnoses, they were rarely seen as the reason for admission by the documenting teams and thus not perceived as a specific focus for palliative care. The described specific palliative care needs have to be taken into account when planning inpatient or outpatient care for these patient groups, but also for the implementation of a palliative care approach in neurological and oncological services. More specifically, social or psychological support should be provided early and appropriately for patients with malignant cerebral involvement and their families to prevent family members from increasing distress and overburdening. Therefore, in services that care to a greater extent for palliative care patients with central malignancies, multi-professional structures with a focus on social work and psychology are of major importance. Offering respite care may be an additional and reasonable preventative intervention. This study has some limitations. The categories presented in the documentation tool were developed with “general” palliative care patients. Issues specific for patients with brain tumours may therefore be underrepresented. As there are still only very few neurologically trained physicians in palliative care, some neurological problems may have been overlooked and the data presented may underestimate the real situation. Furthermore, the documented symptoms and problems were assessed by staff and not by the patients themselves. As many of the documented patients in our study suffered from cognitive impairment, it may be assumed that the use of self-assessment would lead to a selection bias in favour of patients with better cognitive function. Even though there was no evaluation of the severity of cognitive impairment beyond staff assessment on a categorical scale, the routinely performed testing of the cognitive function of patients with brain malignancies at admission, for example with the Mini Mental State Examinations, may have strengthened the results of this study.

Conclusion

This study demonstrates for the first time on a broad, prospectively collected data pool that palliative care problems and needs in patients with primary and secondary brain tumours are significantly different compared with those of other patients. This information can be used for designing best possible palliative care. Specific palliative care problems and reasons for health care utilisation reveal the need for an appropriate provision of interdisciplinary and multi-professional care, with a particular view on the needs of the family caregivers and an early integration of social and psychological support.
  20 in total

1.  How do patients with primary brain tumours die?

Authors:  C Bausewein; P Hau; G D I Borasio; R Voltz
Journal:  Palliat Med       Date:  2003-09       Impact factor: 4.762

2.  What are the problems in palliative care? Results from a representative survey.

Authors:  Lukas Radbruch; Friedemann Nauck; Christoph Ostgathe; Frank Elsner; Claudia Bausewein; Martin Fuchs; Gabriele Lindena; Karl Neuwöhner; Dieter Schulenberg
Journal:  Support Care Cancer       Date:  2003-05-28       Impact factor: 3.603

Review 3.  Germany: Cancer pain and palliative care--current situation.

Authors:  Lukas Radbruch; Friedemann Nauck; Rainer Sabatowski
Journal:  J Pain Symptom Manage       Date:  2002-08       Impact factor: 3.612

Review 4.  Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications.

Authors:  J S Smith; R B Jenkins
Journal:  Front Biosci       Date:  2000-01-01

5.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

6.  Malignant cerebral glioma--II: Perspectives of patients and relatives on the value of radiotherapy.

Authors:  E Davies; C Clarke; A Hopkins
Journal:  BMJ       Date:  1996-12-14

7.  Genetic pathways to glioblastoma: a population-based study.

Authors:  Hiroko Ohgaki; Pierre Dessen; Benjamin Jourde; Sonja Horstmann; Tomofumi Nishikawa; Pier-Luigi Di Patre; Christoph Burkhard; Danielle Schüler; Nicole M Probst-Hensch; Paulo César Maiorka; Nathalie Baeza; Paola Pisani; Yasuhiro Yonekawa; M Gazi Yasargil; Urs M Lütolf; Paul Kleihues
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

8.  [What is the profile of palliative care in Germany. Results of a representative survey].

Authors:  L Radbruch; C Ostgathe; F Elsner; F Nauck; C Bausewein; M Fuchs; G Lindena; K Neuwöhner; D Schulenberg
Journal:  Schmerz       Date:  2004-06       Impact factor: 1.107

9.  Drugs in palliative care: results from a representative survey in Germany.

Authors:  Friedemann Nauck; Christoph Ostgathe; Eberhard Klaschik; Claudia Bausewein; Martin Fuchs; Gabriele Lindena; Karl Neuwöhner; Dieter Schulenberg; Lukas Radbruch
Journal:  Palliat Med       Date:  2004-03       Impact factor: 4.762

10.  What is palliative care in Germany? Results from a representative survey.

Authors:  Lukas Radbruch; Friedemann Nauck; Martin Fuchs; Karl Neuwöhner; Dieter Schulenberg; Gabriele Lindena
Journal:  J Pain Symptom Manage       Date:  2002-06       Impact factor: 3.612

View more
  33 in total

1.  [Accompanying evalution of funded projects in palliative medicine of the German Cancer Aid].

Authors:  C Ostgathe; G Lindena; N Heussen; K Knübben; F Elsner; L Radbruch
Journal:  Schmerz       Date:  2011-12       Impact factor: 1.107

2.  Is there a role for neurologist in an oncological home care team?

Authors:  Giampiero Porzio; Federica Aielli; Lucilla Verna; Francesco Martella; Catia Capannolo; Alejandra Palma; Paolo Aloisi; Corrado Ficorella
Journal:  Neurol Sci       Date:  2012-01-19       Impact factor: 3.307

Review 3.  Systematic review of supportive care needs in patients with primary malignant brain tumors.

Authors:  Elizabeth Ford; Susan Catt; Anthony Chalmers; Lesley Fallowfield
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

4.  Symptoms and medication management in the end of life phase of high-grade glioma patients.

Authors:  J A F Koekkoek; L Dirven; E M Sizoo; H R W Pasman; J J Heimans; T J Postma; L Deliens; R Grant; S McNamara; G Stockhammer; E Medicus; M J B Taphoorn; J C Reijneveld
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

5.  Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire.

Authors:  Eefje M Sizoo; Linda Dirven; Jaap C Reijneveld; Tjeerd J Postma; Jan J Heimans; Luc Deliens; H Roeline W Pasman; Martin J B Taphoorn
Journal:  J Neurooncol       Date:  2013-10-29       Impact factor: 4.130

6.  Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy - a Pilot Project.

Authors:  Jan Gaertner; Rachel Wuerstlein; Ursula Klein; Dennis Scheicht; Sebastian Frechen; Jürgen Wolf; Martin Hellmich; Peter Mallmann; Nadia Harbeck; Raymond Voltz
Journal:  Breast Care (Basel)       Date:  2011-06-14       Impact factor: 2.860

7.  Home care for brain tumor patients.

Authors:  Andrea Pace; Veronica Villani; Antonella Di Pasquale; Dario Benincasa; Lara Guariglia; Sonia Ieraci; Silvia Focarelli; Carmine Maria Carapella; Alfredo Pompili
Journal:  Neurooncol Pract       Date:  2014-03

Review 8.  The end-of-life phase of high-grade glioma patients: a systematic review.

Authors:  Eefje M Sizoo; H Roeline W Pasman; Linda Dirven; Christine Marosi; Wolfgang Grisold; Günther Stockhammer; Jonas Egeter; Robin Grant; Susan Chang; Jan J Heimans; Luc Deliens; Jaap C Reijneveld; Martin J B Taphoorn
Journal:  Support Care Cancer       Date:  2013-12-14       Impact factor: 3.603

9.  Dying with dementia: symptom burden, quality of care, and place of death.

Authors:  Luis Carlos Escobar Pinzon; Matthias Claus; Klaus Maria Perrar; Kirsten Isabel Zepf; Stephan Letzel; Martin Weber
Journal:  Dtsch Arztebl Int       Date:  2013-03-22       Impact factor: 5.594

10.  The end-of-life phase of high-grade glioma patients: dying with dignity?

Authors:  Eefje M Sizoo; Martin J B Taphoorn; Bernard Uitdehaag; Jan J Heimans; Luc Deliens; Jaap C Reijneveld; H Roeline W Pasman
Journal:  Oncologist       Date:  2013-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.